- Novo Nordisk shares plunged in early trading after the company laid out a long-term strategy at its capital markets day, pledging more than five blockbuster drugs and more than $23 billion in new pipeline sales by 2035.
- Investors wanted specific steps to replace Wegovy and Ozempic growth as those patents run out at the start of the next decade; the plan delivered broad vision statements instead.
- The Danish drugmaker lost its lead in the obesity market to Eli Lilly, which is the backdrop for the investor push for a credible turnaround plan under CEO Mike Doustdar.
- Shares recovered somewhat from the initial drop but remained down 4.2%, with the capital markets day still ongoing and more detail expected from executives.
- Novo Nordisk said it plans to diversify beyond treating patients into a broader consumer segment and will look at M&A to build out that push.
Quotes
“Novo Nordisk shares plunged in early trading as the company pledged to launch more than five blockbuster drugs and deliver more than $23 billion in new sales in coming years.”
“investors were clearly not happy with the answers that that they got”
“it wants to broaden the scopes from targeting just patients to to a broader kind of consumer segment”